Filter Results:
(1,440)
Show Results For
- All HBS Web
(1,440)
- People (1)
- News (375)
- Research (870)
- Events (5)
- Multimedia (25)
- Faculty Publications (422)
Show Results For
- All HBS Web
(1,440)
- People (1)
- News (375)
- Research (870)
- Events (5)
- Multimedia (25)
- Faculty Publications (422)
- Web
Aligning Reimbursement with Value - Institute For Strategy And Competitiveness
Measure Outcomes & Cost for Every Patient Aligning Reimbursement with Value Systems Integration Geography of Care Information Technology Aligning Reimbursement w... Aligning Reimbursement with Value Value-based View Details
- 2023
- Working Paper
Are Hospital Quality Indicators Causal?
By: Amitabh Chandra, Maurice Dalton and Douglas O. Staiger
Hospitals play a key role in patient outcomes and spending, but efforts to improve their quality are hindered because we do not know whether hospital quality indicators are causal or biased. We evaluate the validity of commonly used quality indicators, such as... View Details
Keywords: Quality; Health Care and Treatment; Measurement and Metrics; Outcome or Result; Health Industry
Chandra, Amitabh, Maurice Dalton, and Douglas O. Staiger. "Are Hospital Quality Indicators Causal?" NBER Working Paper Series, No. 31789, October 2023.
- 01 Sep 2023
- News
Money Does Grow on (Family) Trees
first genetic tests focused on ancestry were coming on the market. Though they were expensive and of limited utility, Cusenza saw the science rapidly improving, and he recognized opportunity not just in the health care sector but also in... View Details
- Web
2023 Reunion Presentations - Alumni
entrepreneurs view problems as opportunities. In this talk, I focus on entrepreneurs trying to deliver better health and education outcomes at lower cost and in less time. I also discuss the role of ventures... View Details
- July 2019
- Article
The Impact of Price Regulation on the Availability of New Drugs in Germany
By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari
The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate... View Details
Keywords: Regulation; Pharmaceuticals; Healthcare; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Germany
Stern, Ariel Dora, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. "The Impact of Price Regulation on the Availability of New Drugs in Germany." Health Affairs 38, no. 7 (July 2019): 1182–1187.
- 18 Jul 2023
- News
The First Five Years: Brooke Biederman (MBA 2019)
work in watches. Next, Discovery, a South African health care company, incentivizes healthy behavioral change that leads to fewer claims and lower premiums for customers as the company's cost to serve them... View Details
Keywords: Robert Bochnak
- 14 Feb 2023
- HBS Case
Is Sweden Still 'Sweden'? A Liberal Utopia Grapples with an Identity Crisis
Sweden has long seemed like a social-welfare capitalist dream come true, where companies and labor unions collaborate in harmony with government support. Swedish citizens are among the wealthiest in the world, and they enjoy publicly provided View Details
Keywords: by Lane Lambert
- April 2017
- Supplement
Imprimis (B)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A). It describes the company’s decision to enter into the pharmaceutical compounding business in 2013–2014. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients’... View Details
Keywords: Healthcare; Drug Compounding; Drug Development; Pharmaceuticals; Small Business; Decision-making, Business Model; Mark Baum; Imprimis; Decision Making; Strategy; Health Care and Treatment; Policy; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (B)." Harvard Business School Supplement 717-496, April 2017.
- 14 Feb 2017
- First Look
First Look at New Research: February 14
in queue characteristics, we find that, on average, deviations lead to slower completion times, providing evidence of the costs of exercising discretion. Doctors tend to deviate more, and deviations tend to be less detrimental with... View Details
Keywords: Sean Silverthorne
- 07 Feb 2022
- Research & Ideas
Digital Transformation: A New Roadmap for Success
digital-first incumbents struggle to make the necessary longer-term investments when their investors focus on shorter-term metrics, participants say. At the same time, companies must deliver value at speed. They’re cutting costs through... View Details
- 01 Sep 2023
- News
Solving for Z
With nearly 20 years of experience as a senior human resources executive, Matthew Breitfelder (MBA 2002) has seen a lot of change in the corporate talent space. But what’s happening now looks like a tectonic generational shift. From his perch as global head of human... View Details
- 23 Jan 2008
- First Look
First Look: January 23, 2008
Molded) grommet, was supported heavily by the product development group because it was simpler to design and improved the leak seat. Process development was against using it because it cost more, complicated the manufacturing process, and... View Details
Keywords: Martha Lagace
- 21 Oct 2008
- First Look
First Look: October 21, 2008
Working PapersCan Higher Prices Stimulate Product Use? Evidence from a Field Experiment in Zambia (revised) Authors:Nava Ashraf, James Berry, and Jesse M. Shapiro Abstract The controversy over whether and how much to charge for health... View Details
Keywords: Martha Lagace
- 02 Sep 2015
- What Do You Think?
What's Wrong With Amazon’s Low-Retention HR Strategy?
the opportunity to earn high compensation--but jobs that often become too demanding for some employees, particularly those with health problems or family obligations. Former employees complained about bosses who lacked empathy for... View Details
- February 2018
- Article
Development and Feasibility of Bundled Payments for the Multidisciplinary Treatment of Head and Neck Cancer: A Pilot Program
By: Tracy Spinks, Alexis Guzman, Beth M. Beadle, Seohyun Lee, Ron Walters, Jim Incalcaterra, Ehab Hanna, Amy Hessel, Randal Weber, Sandra Denney, Lee Newcomer and Thomas W. Feeley
Purpose:
Despite growing interest in bundled payments to reduce the costs of care, this payment method remains largely untested in cancer. This 3-year pilot tested the feasibility of a 1-year bundled payment for the multidisciplinary treatment of head and neck... View Details
Spinks, Tracy, Alexis Guzman, Beth M. Beadle, Seohyun Lee, Ron Walters, Jim Incalcaterra, Ehab Hanna, Amy Hessel, Randal Weber, Sandra Denney, Lee Newcomer, and Thomas W. Feeley. "Development and Feasibility of Bundled Payments for the Multidisciplinary Treatment of Head and Neck Cancer: A Pilot Program." Journal of Oncology Practice 14, no. 2 (February 2018): e103–e121.
- Web
Leadership Fellows
students and through the candidate selection and interview process. Ensures sufficient resources to support the experience of an MBA. Commits to pay $65,000 toward the Fellow’s annualized salary plus the costs associated with providing... View Details
- 05 Jun 2007
- First Look
First Look: June 5, 2007
Case 707-559 Describes the joint efforts of the German health plan KKH and Essen University Hospital to develop an integrated practice unit (IPU), and the West German Headache Center's efforts to improve the quality of migraine care.... View Details
Keywords: Martha Lagace
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details
Keywords: Policy; Government Legislation; Health Care and Treatment; Negotiation; Price; Pharmaceutical Industry
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
- Web
Finance - Faculty & Research
including an ( S, s ) cost of implementing such policies. We illustrate how this friction goes a long way toward bringing the model closer to the data. When the extended model is calibrated for each of the countries in the new dataset, we... View Details
- Web
Leadership - Faculty & Research
Keywords: Integrated Practice Units ; Outcomes Measurement ; Time-Driven Activity-Based Costing ; Health Care and Treatment ; Business Strategy ; Leading Change ; Decisions ; Transformation ; Service... View Details